ProCE Banner Activity

NADIM II: Survival Results From Phase II Study of Nivolumab + Chemotherapy vs Chemotherapy as Neoadjuvant Treatment for Resectable IIIA-B NSCLC

Slideset Download
Conference Coverage
Neoadjuvant therapy with nivolumab plus CT significantly improved PFS and OS compared with CT alone in patients with resectable stage IIIA-B NSCLC, consistent with the previously reported improvement in pCR.

Released: August 18, 2022

Expiration: August 17, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc